NatResCancer Profile Banner
Cancer at Nature Portfolio Profile
Cancer at Nature Portfolio

@NatResCancer

Followers
6K
Following
2K
Media
96
Statuses
4K

The latest articles, covering all aspects of cancer research, and news from cancer-handling editors at Nature Portfolio journals.

London, New York, Berlin, Shanghai
Joined October 2017
Don't wanna be here? Send us removal request.
@NatureMedicine
Nature Medicine
1 year
The I-SPY trial platform was designed to accelerate development of #neoadjuvant treatments for early-stage #breastcancer and provides a model for future response-adapted clinical trials. News & Views from @JavierCortesMD & colleagues https://t.co/KZNBnLaL2Q
nature.com
Nature Medicine - The I-SPY clinical trial platform was designed to accelerate clinical development of neoadjuvant treatments for early-stage breast cancer. Although it is not without limitations,...
0
2
10
@NatureRevCancer
Nature Reviews Cancer
1 year
In our latest #JournalClub, Chae & Chung (@snuh_official) discuss a study characterizing the differentiation & maturation of both tumour-resident and circulating B cells in patients with melanoma. 📖👉 https://t.co/lHGXc3Qn6e
0
2
2
@EACRnews
EACR
1 year
How can you increase the impact of your own research beyond the publication impact factor? 🤔 Our podcast guests @IACR_DIR, @FJCarmonas & Caroline Dive (@CRUKLungCentre) discuss this in episode 7 of The Cancer Researcher Podcast: https://t.co/wKcsKyGIEp #CancerResearch
0
3
3
@FJCarmonas
Javier Carmona 🇪🇺
1 year
Shifting from a profit-driven model to one that prioritizes affordability and access to advanced medicines for #patients. A timely and much needed Perspective by Melinda Kliegman and colleagues @igisci “A roadmap for affordable genetic medicines” https://t.co/7UxaJgFfzR @Nature
Tweet card summary image
nature.com
Nature - Implementation of new pricing and business structures and improved licensing and manufacturing processes could reduce the per-patient cost of gene therapy tenfold.
0
2
12
@NatureComms
Nature Communications
1 year
Ghosh et al. analyse impact on protein expression, biochemical properties, and evolutionary conservation of all C-terminal nonstop extension mutations registered in the pan-cancer NonStopDB dataset #CancerResearch @NatResCancer
Tweet card summary image
nature.com
Nature Communications - Nonstop extension mutations in cancer remain poorly characterized. Here, the authors test the impact of 2335 tumor-derived C-terminal nonstop extensions on protein...
0
2
5
@NaturePortfolio
Nature Portfolio
1 year
A Review in @NatRevDrugDisc provides an overview of the dynamics of the nerve-cancer cell interplay and discusses the current preclinical and clinical evidence of the benefits of targeting the nervous system in cancer. 🔒 https://t.co/PmIfk0coqN
0
17
62
@CancerCoreEU
Cancer Core Europe
1 year
Great turnout at the #CCE Clinical Trials & Translational Research reception in Barcelona! It was wonderful to see the working group come together to connect and network. Many thanks to all attendees ✨ #ESMO24 #ClinicalTrials #CCE_DART #BoBTrial
1
7
21
@NatImmunol
Nature Immunology
1 year
Muppidi and colleagues find that loss of the G-protein Gα13 suppressed diffuse large B cell lymphoma formation in the mesenteric lymph nodes by limiting the effects of dietary nutrients. Read it here: https://t.co/UoYRLifsUK https://t.co/Kgx7h9iE3J
Tweet card summary image
nature.com
Nature Immunology - Muppidi and colleagues show that loss of Gα13 drives B cell lymphomas preferentially in the mesenteric lymph nodes. They find that Gα13 is required to counteract...
0
6
14
@NaturePortfolio
Nature Portfolio
1 year
Whole-genome sequencing of more than 2,000 colorectal carcinoma samples provides a highly detailed view of the genomic landscape of colorectal cancer and identifies new driver mutations, according to a paper in @Nature. https://t.co/dqNWmCtxaj
0
46
127
@NaturePortfolio
Nature Portfolio
1 year
A Comment article in @NatRevGastroHep discusses how the western lifestyles causes metaflammation, which might prime committed cell lineages to initiate colon tumorigenesis. At-risk individuals might include cases of early-onset colon cancer. 🔒 https://t.co/MkxshhHY9N
0
10
28
@NatureBiotech
Nature Biotechnology
1 year
There is an urgent need for more effective strategies to preselect patients for therapies, mitigating the risk of administering ineffective, potentially harmful drugs and speeding up the process for patients to receive the most effective treatment https://t.co/aL86VDd37Y
0
19
45
@ItaiYanai
Itai Yanai
1 year
Published today! We found that cancer cells adapting to drug treatments don't simply switch from a sensitive to resistant state; instead there's a ‘resistance continuum’ of resistant phenotypes with epigenetically reprogrammed states. 🧵⬇️ https://t.co/Jgx79K3i3a @Gustavo_SFranca
32
393
2K